

## The Small Heterodimer Partner SHP Attenuates Renal Inflammation through Inhibition of ROS Production in Ischemia Reperfusion Injury

Jung Sun Park<sup>1</sup>, Hoon In Choi<sup>1</sup>, Eun Hui Bae<sup>1</sup>, Seong Kwon Ma<sup>1</sup>  
JongUn Lee<sup>2</sup>, Soo Wan Kim<sup>1</sup>

Departments of Internal Medicine<sup>1</sup>, Chonnam National University Medical School  
Departments of Physiology<sup>2</sup>, Chonnam National University Medical School

**Background:** The orphan nuclear receptor, small heterodimer partner (SHP; NROB2), appears to play a negative regulatory role in innate immune responses and contribute to various inflammatory signaling and transcriptional regulation. We investigated whether SHP attenuates renal inflammation in ischemia reperfusion (I/R) and H<sub>2</sub>O<sub>2</sub>-induced kidney injury in human proximal tubular (HK2) cells.

**Methods:** Mouse I/R injury was induced by clamping both renal pedicle for 30 min, and sacrificed 24 hr later. In vitro study, human proximal tubular (HK2) cells were incubated with H<sub>2</sub>O<sub>2</sub> 0, 300, 500, 1000  $\mu$ M for 6 hr. Cell viability was examined using MTT assay. The fluorescent probe 2',7'-DCF-DA was used to measure intracellular levels of reactive oxygen species (ROS). The protein expression of NF- $\kappa$ B, mitogen-activated protein kinase (MAPK), iNOS, COX-2, TNF $\alpha$ , and IL-1 $\beta$  was determined by semiquantitative immunoblotting and RT-PCR. The promoter activity of SHP, NF- $\kappa$ B, and AP-1 was determined by luciferase assay.

**Results:** I/R kidney injury and H<sub>2</sub>O<sub>2</sub> treatment in HK2 cells decreased cell viability, increased production of ROS and induced expression of inflammatory proteins such as iNOS and COX-2. I/R kidney injury and H<sub>2</sub>O<sub>2</sub> treatment in HK2 cells induced the activation of p-ERK1/2, p-p38, and p-JNK MAPK pathway as well as NF- $\kappa$ B nuclear transactivation. Transient transfection of SHP increased cell viability and prevented the H<sub>2</sub>O<sub>2</sub>-induced ROS production as well as reduced protein expression of iNOS, COX-2. In addition, overexpression of SHP prevented H<sub>2</sub>O<sub>2</sub> induced increased expression of MAPK pathway and nuclear activation of NF- $\kappa$ B. H<sub>2</sub>O<sub>2</sub> treatment decreased SHP luciferase activity, which was recovered by MAPK inhibitors (PD980590, SB203580, SP600125) and NF- $\kappa$ B inhibitor (Bay11-7082). Accordingly, H<sub>2</sub>O<sub>2</sub>-induced ROS production and decreased SHP promoter activity were counteracted by ROS scavenger (N-acetyl cysteine, NAC). H<sub>2</sub>O<sub>2</sub> also induced NF- $\kappa$ B and AP-1 promoter activity. Dominant negative mutant (C-jun), specific inhibitor of NF- $\kappa$ B, NAC and overexpression of SHP were able to suppress H<sub>2</sub>O<sub>2</sub>-induced NF- $\kappa$ B and AP-1 promoter activation. The suppressive effect of SHP on the activation of NF- $\kappa$ B and AP-1 were confirmed by an electrophoretic mobility shift assay.

**Conclusions:** These findings suggest that SHP attenuates I/R and H<sub>2</sub>O<sub>2</sub>-induced kidney injury by counteracting inflammatory response through inhibition of MAPK, NF- $\kappa$ B, and AP-1 signal pathway.

**Key Words:** SHP, IR injury